跳到正文
FDA 官方药品与生物制品信息·· 9 天前AI 评分46

FDA 对 Genuine Virgin Aloe Corp(dba Triderma)警告信 CMS 679744 发出关闭函(2026年11月3日)

Genuine Virgin Aloe Corp dba Triderma - 679744 - 11/03/2026

AI 导读

FDA 已于2026年11月3日就 Genuine Virgin Aloe Corp(dba Triderma)2024年7月1日警告信 CMS 679744 所涉违规的纠正措施完成评估,发出关闭函,认为该公司已处理警告信中的违规项。FDA 表示后续检查与监管活动将进一步评估这些纠正措施的充分性与可持续性,该函不免除公司持续合规的责任,也不排除未来监管行动。

正文 · 原文

CLOSEOUT LETTER

Genuine Virgin Aloe Corp dba Triderma MARCS-CMS 679744 — November 03, 2026

Reference #:
FEI 3008235829
Product:
Drugs

Recipient:

Recipient Name

Ms. Gloria J. Vanderlaan

Recipient Title

Founder and CEO

Genuine Virgin Aloe Corp dba Triderma

1395 N. Manassero St.
Anaheim, CA 92807
United States

gloria@triderma.com
Issuing Office:
Division of Pharmaceutical Quality Operations IV

United States

Secondary Issuing Offices

United States


Dear Ms. Vanderlaan:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter CMS 679744 dated July 1, 2024.

Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.

The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S
Andrew Haack
Compliance Officer
Division of Drug Quality III
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research

来源:FDA 官方药品与生物制品信息 · fda.gov

事件后续 · 1

查看事件全部